The Federal Trade Commission (FTC) sent Warning Letters to three companies that sell products containing cannabidiol (CBD) and advertise that the products prevent, treat, or cure disease without substantiation of the purported health benefits. In a post on Husch Blackwell’s Food & Ag Insights blog, Emily Lyons explains the FTC’s actions and the effect they have on the advertising of CBD products.
Continue Reading FTC Issues Warning Letters to Three CBD Companies
FDA
FDA Requests Data on CBD and Other Cannabis-Derived Compounds
Today, the U.S. Food and Drug Administration held a meeting to discuss its regulatory approach to products that contain cannabis and cannabis-derived compounds, including cannabidiol (CBD). Read more about what topics FDA expressed interest in receiving comments.
TTB Prohibits use of CBD in Alcoholic Beverages
The Alcohol and Tobacco Tax and Trade Bureau (TTB) recently issued an industry circular which makes clear that cannabidiol (CBD), a product derived from hemp, is not permitted in alcohol beverages.
Read the full post here.
Clarity at Last? FDA Announces Plans for Meeting on Cannabis-Derived Compounds
On Wednesday, April 3, 2019, the U.S. Food and Drug Administration (FDA) announced plans to hold a meeting to discuss its regulatory approach to products that contain cannabis and cannabis-derived compounds, including cannabidiol (CBD). The public hearing, which is scheduled to be held on May 31, 2019, is intended to obtain scientific data and information…
Unique Issues with Cannabis-related Patents and Their Enforcement
Chapter 1 – The Double-Edged Nature of the FDA Approval Process
2018 proved to be a very busy (and frankly dizzying) year for the cannabis industry as three more states, including Missouri, passed laws legalizing some form of cannabis use, bringing the total number of such states and U.S. territories to well over thirty, despite the fact that cannabis, and its use, remains unlawful, under federal law that is. Today, there are thirty-three states that allow for medical use of cannabis, while ten states have legalized the recreational use of cannabis. What is more, several state governments and governors are expected to prioritize new cannabis-related policies in 2019. As more states decide to permit various uses of cannabis, one issue that remains generally unanswered lies at the intersection of these emerging state laws and U.S. patent law, which falls within the exclusive purview of the federal government, both statutorily and in enforcement of patent rights.Continue Reading Unique Issues with Cannabis-related Patents and Their Enforcement
FDA’s CBD Actions and the Potential Effects on the CBD Market
As many in the marijuana and hemp industry are aware, the Food and Drug Administration (FDA) has recently turned its focus on cannabidiol (CBD). In 2015 alone, the FDA has sent 7 warning letters to companies that are currently marketing CBD in various forms as a dietary supplement. While some in the hemp CBD market…